Gabaeron Inc Profile last edited on: 10/8/2019
CAGE: 809D2
UEI: RVDNEZQNYZN3
Business Identifier: Therapeutics to preserve (restore) brain function in Alzheimers disease 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 11
County: San Francisco
Congr. District: 11
County: San Francisco
Public Profile
Spun out of the Gladstone Institutes - an internationally-known 450 person facility affiliated with the University of California San Francisco and structured around work in the spaces of heart disease, cholesterol metabolism and Alzheimers disease - GABAeron as a start-up biotech company intended to focus specifically on Alzheimers disease. GABAeron is addressing engineered stem cell lines, genetic data and small-molecule drugs ias part of a concerted effort to develop therapeutics to preserve and maybe restore brain function in Alzheimers disease. .
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2021 | 2 | NIH | $2,508,256 | |
| Project Title: Develop Gabaergic Neuron Protectors for Treating APOE4-Related Alzheimer's Disease | ||||
| 2020 | 2 | NIH | $2,223,090 | |
| Project Title: Somatostatin (Sst)-Gabaergic Interneuron Therapy for Alzheimer's Disease with Apoe4 | ||||
Key People / Management
Robert W Mahley -- Senior investigator
Wen-Chin (Danny) Huang Scientist -- Scientist
Wen-Chin (Danny) Huang Scientist -- Scientist
Company News
There are no news available.
